Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1186 to 1200 of 1423 results for primary care

  1. Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)

    Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment.

    Technology appraisal guidance
    Published
    6 January 2021
    View recommendations

    Sections for TA668

  2. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment (HTG694)

    Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication.

    HealthTech guidance
    Published
    26 September 2023
    View recommendations

    Sections for HTG694

  3. Long‑term consequences of planning birth in different settings: What are the long‑term consequences for women and babies of planning birth in different settings?

    compared by accessing medical records and through qualitative interviews. Primary outcomes are long‑term physical morbidity, pain after...

    Research recommendation
    Published
    6 January 2023

  4. Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)

    Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a docetaxel-containing regimen.

    Technology appraisal guidance
    Last updated
    27 July 2016
    View recommendations

    Sections for TA259

  5. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (TA862)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.

    Technology appraisal guidance
    Published
    1 February 2023
    View recommendations

    Sections for TA862

  6. Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

    Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.

    Technology appraisal guidance
    Published
    23 February 2011
    View recommendations

    Sections for TA214

  7. Bone mineral density (BMD) with FRAX:- What is the added prognostic value of BMD in the assessment of fracture risk with FRAX?

    scanning equipment. Currently, there are no definitive studies in primary or secondary care evaluating whether the addition...

    Research recommendation
    Published
    9 June 2015

  8. Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

    Discontinued Reference number: GID-TA10764

    Technology appraisal guidance
    Discontinued

  9. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

    Highly specialised technologies guidance
    Discontinued

  10. Angioplasty versus bypass surgery for treating people with critical limb ischaemia caused by disease of the infra-geniculate arteries:- What is the clinical and cost effectiveness of a 'bypass surgery first' strategy compared with an 'angioplasty first' strategy for treating people with critical limb ischaemia caused by disease of the infra-geniculate (below the knee) arteries?

    infra-geniculate (below the knee) arteries in the calf. For many years, the standard of care has been bypass surgery. Although such...

    Research recommendation
    Published
    9 June 2015

  11. Education about the latent first stage of labour: Does enhanced education specifically about the latent first stage of labour increase the number of nulliparous women who wait until they are in established labour before attending the obstetric or midwifery unit (or calling the midwife to a home birth), compared with women who do not receive this education?

    established labour, and a group who have not received this focused education. Primary outcomes would be mode of birth, satisfaction with...

    Research recommendation
    Published
    6 January 2023

  12. Smart Peak Flow for monitoring asthma (MIB282)

    NICE has developed a medtech innovation briefing (MIB) on Smart Peak Flow for monitoring asthma .

    Medtech innovation briefing
    Published
    11 January 2022

  13. Pharmacological prevention: In people in hospital who are at high risk of delirium, which medication (atypical antipsychotics, typical antipsychotics, benzodiazepines or acetylcholinesterase inhibitors), compared with placebo or each other, is more clinically and cost effective in preventing the development of delirium?

    high risk could be those with 2 or more risk factors for delirium). The primary outcome should be the incidence of delirium, measured at...

    Research recommendation
    Published
    3 February 2023

  14. Intensive rehabilitation therapies after hip fracture: What is the clinical and cost effectiveness of additional intensive physiotherapy and/or occupational therapy (for example, progressive resistance training) after hip fracture?

    applicable) Why this is important?The rapid restoration of physical and self-care functions is critical to recovery from hip fracture,...

    Research recommendation
    Published
    3 February 2023

  15. Interventional procedures programme manual (PMG28)

    This guide describes the methods that NICE follows when evaluating interventional procedures. Processes for interventional procedures are in section 1 of the NICE HealthTech programme manual